Lupin Ltd. and Lupin Pharmaceuticals continue to challenge Genzyme Corporation’s U.S. Patent No. 5,667,775, which expires in 2014.
The Company received notice in 2009 from Lupin that it had submitted to…
Fresenius Medical Care Holdings, Inc.’s liability for infringing valid claims of Baxter International Inc.’s main patent affirmed in September 2009.
Since April 2003, Baxter has been pursuing a patent infringement action…
A trial on Baxter Healthcare Corporation’s patent infringement lawsuit against Fresenius Medical Care Holdings, Inc. and Fresenius USA, Inc., is anticipated in mid-2010.
On Oct. 16, 2006, Baxter Healthcare, a direct…
Merck & Co. Inc. and Schering-Plough Corporation continue to pursue a patent infringement lawsuit against generic pharmaceutical manufacturers who filed abbreviated new drug applications for generic ezetimibe (Zetia).
An abbreviated new…
Teva Pharmaceuticals Inc. has appealed the decision upholding the validity of Merck & Co. Inc.’s Singulair patent.
On Aug. 19, 2009, the U.S. District Court for the District of New Jersey…
Medtronic Inc., on July 27, 2009, announced global resolution of all outstanding intellectual property litigation with Abbott Laboratories.
The terms of the agreement stipulate that neither party will sue each other…
Amgen Inc. faces a patent infringement suit by Teva Pharmaceutical Industries Ltd. and Teva Pharmaceuticals USA, Inc in the U.S. District Court for the Eastern District of Pennsylvania.
On May 20,…
A claims construction hearing in Amgen Inc.’s patent infringement lawsuit against Teva Pharmaceuticals USA, Inc., Teva Pharmaceutical Industries Ltd. and Barr Laboratories, Inc. is set for Jan. 25 and Jan.…
No trial date has been set for Shire Ltd.’s suit against Teva Pharmaceuticals Industries Ltd. for the alleged infringement of U.S. Patent Nos. 5,912,013 and 5,326,570.
Both patents relate to carbamazepine.
The…
Generics UK Ltd.’s appeal to the ruling in its rectification action against Shire Ltd. will be heard in October 2009.
Generics UK seeks a declaration that the duration of the Supplementary…